For immediate release |
4 April 2013 |
Futura Medical plc
("Futura" or "the Company")
Directors' Share Dealings
Futura Medical plc (AIM: FUM), the pharmaceutical group that develops innovative products for consumer healthcare, announces that it has received notification that James Barder, the Chief Executive of the Company has today transferred 35,000 ordinary shares in the Company from his personal account into his personal pension. The transfer involved a sale of Mr Barder's shares at 67.9 pence and a repurchase by the pension of the same number of shares at 68 pence.
No disposal has taken place for the purposes of the AIM Rules for Companies, Mr Barder's aggregate beneficial holding and non-beneficial holdings remains unchanged at 925,330 ordinary shares.
For any further information please contact:
Futura Medical plc |
|
James Barder, Chief Executive
|
Tel: +44 (0)1483 685 670 |
mail to: james.barder@futuramedical.com |
|
|
|
Nomura Code Securities Limited |
|
Phil Walker / Giles Balleny |
Tel:+44 (0)20 7776 1200 |
|
|
For media enquiries please contact: |
|
|
|
Buchanan |
|
Mark Court / Fiona Henson / Sophie Cowles |
Tel: +44 (0)20 7466 5000 |
Notes to Editors
Futura Medical plc
Futura Medical is a pharmaceutical group that develops innovative products for consumer healthcare. The Company is developing a portfolio of products and its strategy is to license their manufacture and distribution to major pharmaceutical and healthcare groups.
Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange.